TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00790400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
Study: NCT03149575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice of Salvage Therapy - temozolomide
Description: The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice of Salvage Therapy - lomustine
Description: The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice of Salvage Therapy - carboplatin
Description: The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate.
Study: NCT03485664

Intervention type: PROCEDURE
Intervention: tooth extraction
Description: tooth extraction

Intervention type: PROCEDURE
Intervention: tooth extraction
Description: tooth extraction
Study: NCT01125033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C & Vitamin E
Description: The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C Placebo & Vitamin E Placebo
Description: The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
Study: NCT03415243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg
Description: Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters \[mcL\]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel \[MBq\] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Description: Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi\[4MBq\]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
Study: NCT03527797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of support level
Description: Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
Study: NCT00078338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone®
Description: Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
Study: NCT03258320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
Description: As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
Study: NCT00672685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-domain intervention
Description: multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-domain intervention
Description: multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OMEGA-3 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OMEGA-3 placebo
Study: NCT00949377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone Bromide (MNTX)
Description: The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02883595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymosin alpha 1
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo (saline) twice per day for seven days
Study: NCT03258723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
Study: NCT02112188

Intervention type: BEHAVIORAL
Intervention: In-depth Patient Interviews

Intervention type: BEHAVIORAL
Intervention: Adaptation of IMCP for Chinese Immigrant Cancer Patients

Intervention type: BEHAVIORAL
Intervention: Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)
Description: The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
Study: NCT06783738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants will come to our lab twice. In the first visit we will perform a fitness assessment, using a noninvasive, cardiopulmonary exercise testing used routinely to measure fitness in children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The participants will come to our lab twice. In the first visit we will perform a fitness assessment, using a noninvasive, cardiopulmonary exercise testing used routinely to measure fitness in children.
Study: NCT00713986

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Water 2mL PO 2 minutes prior to intra-muscular injection
Description: Sterile Water 2mL PO - single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose 25% 2 mL PO 2 minutes prior to injection
Description: Glucose 25% 2mL PO - single dose
Study: NCT02142764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
Study: NCT00879242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
Study: NCT01601509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal tramazoline with dexamethazone
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal placebo
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
Study: NCT01697020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine 20mg/ml oral suspension
Description: 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine 50mg tablet
Description: 50mg
Study: NCT04588259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart
Description: Administered s.c. (subcutaneously, under the skin) for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Administered s.c. (subcutaneously, under the skin) for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Administered s.c. (subcutaneously, under the skin) for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered s.c. (subcutaneously, under the skin) for 16 weeks
Study: NCT04336475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orofacial exercise program
Description: combined stretching\&strengthening exercise regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orofacial exercise program
Description: combined stretching\&strengthening exercise regimen
Study: NCT02228018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-scan
Description: CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
Study: NCT04158505

Intervention type: OTHER
Intervention: non-interventional
Description: This prospective, observational study will be conducted according to each site's routine clinical practice
Study: NCT00510055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subdermal manipulation ONLY
Description: scars receive subdermal manipulation ONLY

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subdermal manipulation AND injection of a filler
Description: scars receive subdermal manipulation AND injection of a filler
Study: NCT02098395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT02382809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC071
Description: Mouthwash, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouthwash, twice daily
Study: NCT00501709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept and Raptiva
Description: immunosuppressant agent to prevent rejection in transplant recipients
Study: NCT01408082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)
Description: Azithromycin and Dexamethasone twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azasite
Description: Azasite twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone twice daily for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 2 weeks
Study: NCT04387409

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VPM1002
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Study: NCT01284751

Intervention type: OTHER
Intervention: MDI - self-rating inventory
Description: MDI with 12 questions to be completed approximately 1 week before surgery
Study: NCT00713986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.
Description: neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
Study: NCT02944929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-rehabilitation program
Description: The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
Study: NCT00872612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA/EBUS-TBNA + BAL
Description: EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBB + TBLB + BAL
Description: EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
Study: NCT02626000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W